Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F annual reports and Form 6‑K current reports. This SEC filings page on Stock Titan centralizes those documents and pairs them with AI‑generated summaries to help readers understand the regulatory information associated with Immuron’s biopharmaceutical business.
Recent Form 6‑K filings furnished by Immuron reference Australian Securities Exchange announcements such as applications for quotation of securities, cleansing notices, CEO addresses, annual general meeting results, changes of director interests, changes of share registry, and clinical and regulatory milestones including FDA approval of the IMM‑529 Investigational New Drug application. These filings provide context on capital management, governance decisions and progress in the company’s clinical programs for Travelan/IMM‑124E, IMM‑529 and IMM‑986.
On this page, you can review Immuron’s 20‑F annual report for a comprehensive description of its operations, risk factors and financial statements, and browse 6‑K current reports that capture material information first released to the Australian Securities Exchange. Where applicable, Stock Titan also surfaces Form 4 and related insider transaction disclosures that are filed in connection with changes in director or executive holdings, as referenced in Immuron’s 6‑K exhibits.
Stock Titan’s AI features highlight key points from lengthy filings, explain technical sections in plain language, and help you locate items such as clinical trial updates, securities issuances and shareholder meeting outcomes. This makes it easier to track how Immuron’s regulatory disclosures align with its strategy in orally delivered targeted polyclonal antibodies and its commercial and clinical activities.
Immuron Limited is offering up to
Immuron Limited is updating its at-the-market share sale program with H.C. Wainwright & Co., increasing the additional aggregate offering capacity by $2,847,954 of American Depositary Shares under their existing At The Market Offering Agreement. These ADSs will be issued under Immuron’s effective shelf registration statement on Form F-3 and related prospectus, as supplemented by a new prospectus supplement dated October 3, 2025. The company also files a legal opinion covering $2,607,382 of securities issuable under the agreement and clarifies that this 6-K is incorporated by reference into the registration statement.
Immuron Limited submitted a Form 6-K as a foreign private issuer to furnish information previously published to the Australian Securities Exchange. The filing primarily forwards a publicly released letter to shareholders, which is included as Exhibit 99.1. The company specifies that this Form 6-K, including its exhibit, is furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if explicitly referenced.
Immuron Limited submitted a Form 6-K to provide an updated consent from its independent registered public accounting firm, Grant Thornton Audit Pty Ltd, dated September 30, 2025. This consent allows Grant Thornton’s audit work and reports to be used in connection with Immuron’s existing shelf registration statement on Form F-3 (File No. 333-280667).
The consent is filed as Exhibit 23.1 and is expressly incorporated by reference into the Form F-3 from the date this report is submitted, unless later filings replace it. The document is administrative in nature and does not present new financial results or major corporate transactions.
Immuron Limited, an Australian-based foreign private issuer, submitted a Form 6-K for September 2025 to provide U.S. investors with information also released on the Australian Securities Exchange. The company reports that it published two ASX announcements and attaches them as an exhibit.
The filing includes Exhibit 99.1, described as an Appendix 4G and Corporate Governance Statement. Immuron specifies that this Form 6-K and its exhibit are furnished, not filed, under the U.S. securities laws and will only be incorporated into other securities filings if explicitly referenced.
Immuron Limited (IMRN) filed a Form 20-F presenting a biotech group focused on hyper-immune products and R&D-stage therapeutics, including its commercial product Travelan.
Reported full-year figures show revenue lines including A$2,599,458 of grant or other income and product sales components (e.g., Travelan US A$1,658,336; Canada A$378,706). Research and development expense was A$3,597,296 and general operating expenses contributed to net operating losses. The group recorded a net decrease in cash and cash equivalents of A$8,837,614 from a starting cash balance of A$11,657,315. The balance sheet shows total assets of A$10,437,270 and total liabilities of A$2,059,491.
Operationally, Immuron disclosed multiple granted patents across jurisdictions and recent PCT filings, continued investment in clinical programs, and an At-The-Market facility raising A$2,809,177 (US$1,822,322) to support at least the next 12 months. The financial statements are prepared on a going concern basis.
Immuron Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish investors with materials already released on the Australian Securities Exchange. The filing attaches two September 2, 2025 announcements: an Appendix 4E Preliminary Final Report and an FY25 results presentation. These exhibits provide the detailed financial and operational results for the fiscal year ended FY25, while the Form 6-K itself clarifies that this information is furnished to U.S. markets but is not deemed filed under the Exchange Act or automatically incorporated into other U.S. securities filings.
Immuron Limited submitted a Form 6-K as a foreign private issuer to furnish recent announcements made to the Australian Securities Exchange. The filing notes that the company published two public notices on August 26, 2025, including one titled “Immuron partners with InvestorHub,” which is attached as Exhibit 99.2.
The company clarifies that this Form 6-K and its exhibit are furnished, not filed, under U.S. securities laws and will only be incorporated into other securities filings if specifically referenced.
Immuron Limited filed a Form 6-K as a foreign private issuer for August 2025 to furnish two announcements previously published on the Australian Securities Exchange. These ASX notices, titled Appendix 3G, are attached, including Exhibit 99.2, a notification regarding unquoted securities for IMC.